Mokhtari et al., International Immunopharmacology,
doi:10.1016/j.intimp.2021.107636 (Peer Reviewed)
Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting
Retrospective 28,759 adult outpatients with mild COVID-19 in Iran, 7,295 treated with HCQ, showing significantly lower hospitalization and mortality with treatment.
Mokhtari et al., 4/6/2021, retrospective, Iran, Middle East, peer-reviewed, 11 authors, dosage 400mg bid day 1, 200mg bid days 2-5.
risk of death, 69.7% lower, RR 0.30, p < 0.001, treatment 27 of 7295 (0.4%), control 287 of 21464 (1.3%), adjusted per study, odds ratio converted to relative risk.
risk of hospitalization, 35.3% lower, RR 0.65, p < 0.001, treatment 523 of 7295 (7.2%), control 2382 of 21464 (11.1%), adjusted per study, odds ratio converted to relative risk.
Effect extraction follows
pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.